Johnson & Johnson’s stock rose 2.4% in premarket trading, enough to pace the Dow Jones Industrial Average’s early gainers.

The health sector is witnessing notable developments. Bristol Myers and Pfizer are offering Eliquis at a discounted rate.

Johnson & JohnsonJNJ, on its second-quarter conference call, stated that it expects its oncology sales to reach $50 billion ...

Analysts expect Johnson & Johnson to report an earnings per share (EPS) of $2.67. Johnson & Johnson bulls will hope to hear ...

Johnson & Johnson shows steady growth in Q2, driven by medtech and oncology, yet talc litigation overshadows. Click for my ...

This week's dividend activity included increased payouts from Citigroup (NYSE:C) and Duke Energy (DUK) as well as ...

Pfizer and Johnson & Johnson are two healthcare giants. Both have a solid earnings growth outlook, but they differ in terms of valuation, as well as in the dividend yields they offer right here.

Johnson & Johnson sought help from its three rival Covid-19 vaccine makers to look into reports of blood clots, but Pfizer and Moderna both declined, the Wall Street Journal reported on Friday ...

Some consumers have been wary of the Johnson & Johnson vaccine because its overall efficacy in clinical trials was 66% compared with about 95% for the Moderna and Pfizer vaccines.

Johnson & Johnson expects to make $2.5 billion in revenue from its COVID-19 vaccine in 2021. That's a drop in the bucket for the mammoth business, which generated more than $80 billion in revenue ...

The Pfizer vaccine is the first to receive FDA approval, while the Moderna and Johnson & Johnson vaccines are available under an emergency use authorization. For children ages 12 to 15 , Pfizer's ...